(3R)-1-[2-[2-(3,4-dimethoxyphenyl)ethoxy]cyclohexyl]pyrrolidin-3-ol

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: (3R)-1-[2-[2-(3,4-dimethoxyphenyl)ethoxy]cyclohexyl]pyrrolidin-3-ol
• 化学式: C₂₀H₃₁NO₄
• 分子量: 349.5
• InChiKey: VBHQKCBVWWUUKN-WWDZGPRUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  25
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  51.2
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• [EN] AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSES A BASE D'AMINOCYCLOHEXYLE-ETHER ET LEURS UTILISATIONS
  申请人：CARDIOME PHARMA CORP

  公开号：WO2004099137A1

  公开（公告）日：2004-11-18

  Aminocyclohexyl ether compounds are disclosed. The compounds of the present invention may be incorporated in compositions and kits. The present invention also discloses uses for the compounds and compositions, including the treatment of arrhythmia.

  本发明披露了氨基环己醚化合物。本发明的化合物可以被纳入到组合物和试剂盒中。本发明还披露了化合物和组合物的用途，包括治疗心律不齐。
• PEGYLATED ION CHANNEL MODULATING COMPOUNDS
  申请人：Cheu Elizabeth L. S.

  公开号：US20100273724A1

  公开（公告）日：2010-10-28

  This invention is directed to PEGlyated derivatives, drug conjugates and isotopic derivatives of certain ion channel modulating compounds. Pharmaceutical compositions and methods of use of also disclosed

  这项发明涉及某些离子通道调节化合物的PEG化衍生物、药物结合物和同位素衍生物。还公开了制药组合物和使用方法。
• Ion channel modulating activity II
  申请人：Fedida David

  公开号：US20050119315A1

  公开（公告）日：2005-06-02

  Methods, compositions, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias. In these methods, arrythmias (e.g. atrial fibrillation, atrial flutter, early afterdepolarizations and prolongation of QT interval) may be reduced or eliminated by administering ion channel modulating compounds to a subject in need thereof. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds. Also described are compositions of ion channel modulating compounds and drugs which induce early afterdepolarizations, prolongation of QT interval and/or Torsades de Pointes.

  治疗或预防心律失常的方法、组合物、给药方案和给药途径。在这些方法中，通过对有需要的受试者施用离子通道调节化合物，可减少或消除心律失常（如心房颤动、心房扑动、早期后极化和 QT 间期延长）。离子通道调节化合物可以是环烷基胺醚化合物，特别是环己胺醚化合物。还描述了离子通道调节化合物和药物的组合物，这些组合物会诱发早期后极化、QT间期延长和/或Torsades de Pointes。
• Aminocyclohexyl ether compounds and uses thereof
  申请人：Cardiome Pharma Corp.

  公开号：EP1666459B1

  公开（公告）日：2011-10-19
• AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF
  申请人：Cardiome Pharma Corp.

  公开号：EP1560812A1

  公开（公告）日：2005-08-10